Table 3. Mutivariate analysis for the prognostic impact of clinical factors on progression free survival and overall survival.
| Progression-free survival | Overall survival | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| B2M (≥ 2.5 mg/L) | 1.70 (1.29–2.24) | < 0.001 | 2.00 (1.47–2.75) | < 0.001 |
| Age (> 60 years) | 1.94 (1.50–2.50) | < 0.001 | 2.13 (1.60–2.83) | < 0.001 |
| ECOG PS (3–4) | 1.65 (1.19–2.28) | 0.003 | 1.70 (1.18–2.39) | 0.003 |
| LDH (> UNL) | 2.12 (1.57–2.87) | < 0.001 | 1.96 (1.39–2.77) | < 0.001 |
| Ann Arbor stage ≥ 3 | 1.42 (1.19–2.20) | 0.002 | 1.68 (1.18–2.39) | 0.004 |
Abbreviations: B2M, beta-2 microglobulin;CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; PS, performance score; UNL, upper normal limit.